After Delays, Nucleonics to Move Hep B Drug To Clinic in '07; Firm Unveils New Rx Goals
November 30, 2006
After Delays, Nucleonics to Move Hep B Drug To Clinic in '07; Firm Unveils New Rx Goals
After struggling with optimization of its hepatitis B drug candidate, Nucleonics is now on track to begin phase I testing in the first quarter of 2007. The company has also initiated preclinical programs in cancer and influenza.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Rosetta Genomics, Prime Health Reach Deal for Coverage of MiRview Mets2 Assay
May 20, 2013 / GenomeWeb Daily News - NIH Awards $400K to Fund Three microRNA Research Grants in May
May 20, 2013 / Gene Silencing News - Regulus Selects HCV Drug Candidate, Will Develop without Partner GSK
May 16, 2013 / Gene Silencing News - Scripps, Novartis Team Uncovers New Details of Guide RNA, Argonaute2 Interaction
May 16, 2013 / Gene Silencing News - Gradalis Releases New Clinical Data on Cancer Vaccine
May 16, 2013 / Gene Silencing News